Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too
Low-risk trials, QoL in PARTNER 3 and COAPT, and the continued volume-outcome discussions made waves this year.
Related Articles
Orthopedic and Radiation Injuries Unchanged in Cath Lab Staff Since 2014
A SCAI survey found high rates of spinal injury amid signs that careers could be longer with better prevention and management.
AHA Offers Help for Clinicians Weighing the Results of DTC Genetic Tests
Patients can now easily buy these tests, but cardiologists must consider their quality when using the information to guide care.
Newer Weight-Loss Drugs Not Cost-effective at Current Prices
Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.
Lower Risk of Mortality for Shock Patients Transferred to Expert Centers
The US data also point to lower costs and shorter stays at these expert centers, an argument for regionalized care akin to STEMI.
Food Insecurity in Adulthood Signals Greater Risk of Later CVD
More research is needed to see how this factor could inform risk tools and whether addressing it reduces future disease.
Danish Analysis Updates Stroke and MI Risks of Contemporary Contraceptives
Though arterial thrombotic risk was higher with hormonal contraception use, the absolute excess risks were low.
Regulating Calcium Could Help Regenerate the Heart
Early data in mice and human tissue indicate that using drugs or gene therapy could allow for cardiac healing in ischemic HF.
SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years
The data raise questions about valve hemodynamics and the role of early imaging to stay ahead of clinical and subclinical issues.
AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years
The DCB looks good in select cases, but given its high price tag, exactly when to use it is still up for discussion, say experts.
CV Screening, Care at UK Football Club Made Inroads Against HF
A one-stop approach resulted in a new diagnosis of HF for 3% of the clinic’s visitors, who then were referred for timely treatment.